Dr. Tolaney on Pembrolizumab Plus Eribulin in TNBC

Dr. Sara Tolaney on Eribulin Plus Pembrolizumab for Metastatic Triple-Negative Breast CancerПодробнее

A Study Investigating Pembrolizumab in Combination With Eribulin in TNBCПодробнее

SABCS 2016 - Sara TolaneyПодробнее

Dr. Tolaney on Platinum-Based Therapy in Neoadjuvant Setting of TNBCПодробнее

Eribulin in Metastatic TNBC: Real-World DataПодробнее

Phase II Results for Pembrolizumab Monotherapy in Metastatic TNBCПодробнее

Sara M. Tolaney, MD, MPH, on the efficacy & safety of combination eribulin + pembrolizumabПодробнее

Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast CancerПодробнее

PD-1 therapy with eribulin for triple negative MBCПодробнее

Secondary Endpoints From a Trial of Pembrolizumab Plus Chemotherapy for Metastatic TNBCПодробнее

Longer Overall Survival in Metastatic TNBC With Pembrolizumab - Medpage TodayПодробнее

Eribulin’s Role in Triple-Negative Breast CancerПодробнее

Harnessing the Immune System in the Treatment of Triple-Negative Breast CancerПодробнее

Dr. Nanda On Pembrolizumab Potential for TNBCПодробнее

Gut microbiome signatures correlate with OS in pts receiving eribulin +/- pembro for HR+ mBCПодробнее

Dr. Hurvitz on Pembrolizumab for TNBCПодробнее

Dr. Tolaney Discusses Patient Selection for Platinum-Based Therapy in TNBCПодробнее

Ladiratuzumab Vedotin Plus Pembrolizumab for Advanced TNBCПодробнее

Eribulin as Treatment for Metastatic Breast CancerПодробнее